オプションチェーンは、Cidara Therapeuticsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Cidara Therapeuticsの市場センチメントを評価します。.

Cidara Therapeutics (NASDAQ:CDTX) 株価情報, オプションチェーン

Cidara Therapeutics

Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.

Cidara Therapeutics Inc

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Guggenheim analyst Seamus Fernandez initiated coverage on Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Buy rating and announced a price target of $33. Cidara Therapeutics shares closed at $13.11 on Thursday. <a href="https://www.benzinga.com/quote/cdtx/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>RBC Capital analyst Leonid Timashev initiated coverage on Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with an Outperform rating and announced a price target of $80. Cytokinetics shares closed at $55.84 on Thursday. <a href="https://www.benzinga.com/quote/cytk/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stephens &amp; Co. analyst Sudan Loganathan initiated coverage on Immunome, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNM#NASDAQ">IMNM</a>) with an Overweight rating and announced a price target of $30. Immunome shares closed at $12.54 on Thursday. <a href="https://www.benzinga.com/quote/imnm/analyst-ratings">See </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">how other analysts view this stock</a>.</li>
<li>Jefferies analyst Dennis Ding initiated coverage on Inhibikase Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) with a Buy rating and announced a price target of $8. Inhibikase Therapeutics shares closed at $2.78 on Thursday. <a href="https://www.benzinga.com/quote/ikt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Ben Shelley initiated coverage on Flutter Entertainment plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>) with a Buy rating and announced a price target of $306. Flutter Entertainment shares closed at $237.98 on Thursday. <a href="https://www.benzinga.com/quote/flut/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CYTK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="544" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084118/image-92-1024x544.png" alt="" class="wp-image-637640" style="width:627px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084118/image-92-1024x544.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084118/image-92-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084118/image-92-768x408.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084118/image-92.png 1237w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></li>
</ul>

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

CDTX

CYTK

FLUT

IMNM

This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Guggenheim analyst Seamus Fernandez initiates coverage on Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Buy rating and announces Price Target of $33.

Price Target

Guggenheim Initiates Coverage On Cidara Therapeutics with Buy Rating, Announces Price Target of $33

HC Wainwright &amp; Co. analyst Ed Arce reiterates Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Buy and maintains $24 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Cidara Therapeutics, Maintains $24 Price Target

Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>), a biotechnology company using its proprietary Cloudbreak&#xAE;&nbsp;platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced two presentations at OPTIONS XII for the Control of Influenza conference, to be held September 29 through October 2, 2024 in Brisbane, Australia. The presentations, one oral and one poster, will highlight safety and pharmacokinetic (PK) data from clinical studies of CD388, Cidara's influenza drug-Fc conjugate (DFC) candidate.

Biotech

General

Cidara Therapeutics Announces Two Presentations On Innovative Drug-Fc Conjugate, CD388, At The 2024 OPTIONS XII For The Control Of Influenza Conference

Cidara Therapeutics Doses First Subjects In Phase 2b NAVIGATE Trial Of CD388 In The Prevention Of Seasonal Influenza

Trading Halt: Halt status updated at 4:30:00 PM ET: Quotation Resumption: News and Resumption Times

Guidance

Management

Cidara Therapeutics Estimates Will Incur Charges Of About $1.2M For Severance Payments And Employee Benefits, Primarily In Q4 2024; Expects To Initiate Phase 2b Clinical Trial Of CD388 For Prevention Of Influenza In Q3 2024

Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>), a biotechnology company using its proprietary Cloudbreak&#xAE; platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced a reduction in its workforce to focus on the clinical development of CD388, the Company's novel DFC candidate for influenza A and B. The planned reduction impacts approximately 30% of the Cidara workforce. &nbsp;
These strategic initiatives are expected to substantially reduce capital needs and allow Cidara to focus on its planned Phase 2b and potential subsequent trials investigating CD388 as a single-dose, universal preventative for influenza A and B. The Company continues business development discussions for its oncology DFC programs, including CBO421, a CD73 inhibitor, which recently received IND-clearance to commence a Phase 1 study.

Cidara Therapeutics Restructures Workforce By 30% To Focus On Planned Clinical Development Of CD388

Trading Halt: Halted at 4:00:15 p.m. ET - Trading Halt: Halt News Pending

HC Wainwright &amp; Co. analyst Ed Arce upgrades Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) from Neutral to Buy and announces $24 price target.

Upgrades

HC Wainwright & Co. Upgrades Cidara Therapeutics to Buy, Announces $24 Price Target

Cantor Fitzgerald analyst Louise Chen reiterates Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Overweight.

Cantor Fitzgerald Reiterates Overweight on Cidara Therapeutics

Needham analyst Joseph Stringer reiterates Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Buy and maintains $25 price target.

Needham Reiterates Buy on Cidara Therapeutics, Maintains $25 Price Target

Cidara Therapeutics Q2 2024 Revenue $302K Vs $5.09M YoY

Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) reported quarterly losses of $(2.28) per share which missed the analyst consensus estimate of $(0.20) by 1040 percent. The company reported quarterly sales of $8.46 million which beat the analyst consensus estimate of $6.30 million by 34.33 percent. This is a 67.44 percent decrease over sales of $25.99 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Cidara Therapeutics Q1 2024 GAAP EPS $(2.28) Misses $(0.20) Estimate, Sales $8.46M Beat $6.30M Estimate

Cidara Therapeutics Regains Compliance With Nasdaq's Requirements For Continued Listing

WBB Securities analyst Stephen Brozak maintains Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Strong Buy, adjusts target to $40 (reverse stock split - 1:20).

WBB Securities Maintains Strong Buy on Cidara Therapeutics, Adjusts Price Target To $40 (reverse stock split - 1:20)

Needham analyst Joseph Stringer maintains Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Buy, adjusts target to $25 from $3.

Needham Maintains Buy on Cidara Therapeutics, Adjusts Price Target To $25

Cidara Therapeutics (CDTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed Arce from H.C...

Cidara Therapeutics Buy Rating Affirmed on Strategic Focus and Promising CD388 Clinical Developments

Q3 pharma and biotech layoffs in charts: More than 1000 each in July and August

Warning: CDTX is at high risk of performing badly

Cidara Therapeutics GAAP EPS of -$2.38 beats by $1.87

"The recent initiation of our Phase 2b NAVIGATE clinical trial, which will evaluate the efficacy and safety of CD388 for the pre-exposure prophylax...

Cidara Therapeutics reports Q3 EPS ($2.45), consensus ($4.25)

Needham analyst Joseph Stringer maintained a Buy rating on Cidara Therapeutics (CDTX – Research Report) today and set a price target of $25.00. Jos...

Positive Outlook for Cidara Therapeutics Amid Strategic Advancements and Financial Stability

ABUS

ALPMF

ALPMY

ANTX

ATHA

BAYRY

BAYZF

BBIO

BMRN

CRBU

CVAC

FGEN

GLYC

HLVX

IBRX

INAB

LXRX

PGEN

QURE

RAPT

RHHBY

RLAY

RPTX

SLRN

VIRX

Health Care

Press Releases

Cidara Therapeutics Announces Appointment of Jim Beitel as Chief Business Officer

Cidara to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Cidara Therapeutics Restructures Workforce to Focus on Planned Clinical Development of CD388

Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts

Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza

Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference

Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Cidara Therapeutics Announces Two Presentations on Drug-Fc Conjugate, CD388, at IDWeek 2024

Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Comments

Cidara Therapeutics

Cidara Therapeutics (CDTX) オプション

Cidara Therapeutics (NASDAQ:CDTX) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル